Swiss digital health company MindMaze has raised $105 million to help take its digital therapeutics (DTx) for neurological diseases like stroke onto the global stage, and fund the developme
A hospital trust has become the first in the UK to deploy a gaming system developed by Swiss company MindMaze that is intended to help patients suffering a stroke to repair their brains.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.